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A Brief Review Of 
Aureomycin 
Alan Raun, V.M. 2 
O F WHAT good is aureomycin to the 
veterinary profession? That's the 
question asked by practicing veterinarians 
as this new antibiotic comes into the 
therapeutic limelight. 
Most of the work done on aureomycin to 
date is experimental and much of that in 
vitro only. However, it appears that this 
new antibiotic has definite therapeutic 
value against various bacterial, ricket-
tsial and virus infections. 
Aureomycin, first reported by Duggarl, 
is the antibiotic procured from the mold, 
Streptomyces aureofaciens, a member of 
the same genus from which streptomycin 
and various other antibiotics have been 
obtained. It has been used on a number 
of human cases, but as yet very little 
material is available on its use in the 
treatment of animal diseases. The follow-
ing is a brief summary of what is known 
of the drug at present. 
Experimental work has shown that 
aureomycin has a low toxicity, practically 
no side reactions and can be administered 
orally, intravenously or intramuscularly. 
However, in intramuscualr injections a 
slight irritation of the perivascular tissue 
surrounding the site of injection some-
times occurs. Following oral doses aureo-
mycin appears in the urine in about one 
hour, is actively secreted for from six to 
twelve hours; and traces may be found in 
the urine as long as three days following 
its administration. Therapeutically effec-
tive concentrations also exist in the cere-
brospinal fluid within six hours following 
an intravenous injection,2 thus proving the 
drug is readily diffused through the blood-
brain barrier. 
At the present time there is no evidence 
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of methemoglobin formation, no chronic 
toxicity resulting from continued ad-
ministration of large doses of the drug. 
No modification of the vasomotor action 
of epinephrine, acetylcholine or histamine 
has been observed. Aureomycin does not 
appear to have any effect on the heart or 
kidneys, nor is the blood sugar level 
affected. 2 
Aureomycin in vitro, was found to be 
highly effective against almost all coccidial 
diseases and many diseases caused by 
Gram-positive and Gram-negative rods. 
Exceptional bacteriostatic action was ob-
served against the following type species: 
Staphylococcus aureus: A common 
etiologic agent in wound infections and 
pyemias of all animals. It causes pustular 
dermatitis and gastroenteritis in dogs and 
mastitis in the bovine. 
Streptococcus zooepidemicus: The com-
mon pathogen of the horse which causes 
abortion, sterility, cervicitis and metritis 
in the mare and navel ill, arthritis and 
septicemias in the foal. It may also cause 
genital and urinary tract infections, calf 
dysentery and mastitis in the bovine. 
Salmonella pullorum: The etiologic 
agent in enteritis and bacteremia in the 
young chick commonly called pullorum 
disease. 
Aerobacter aerogenes: A Gram-nega-
tive bacterium that is one of the causes 
of urinary tract infections in dogs and 
mastitis in the cow. 
Shigella gallinarum: The cause of fowl 
typhoid. 
Erysipelothrix rhusiopathiae: The etio-
logic agent in erysipelas in swine and fowl 
and erysipeloid in man. 
Pasturella multocida: The cause of 
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fo,vl cholera, septicemias in swine, sheep 
and goats and what is commonly called 
hemorrhagic septicemia in cattle. 
• \lso of extreme interest to the vet-
erinary profession is the fact that this new 
antibiotic may prove to be an effective 
combatant of brucellosis in man and 
animals.3 So far, results of aureomycin 
therapy are only available in the treat-
ment of human cases resulting from in-
fection by Brucella organisms. In the 
cases thus far recorded, immediate ther-
apeutic results have surpassed those ob-
tained with any other specific therapy in-
cluding a combination of streptomycin 
and sulfadiazine. Aureomycin has been 
used successfully in the treatment of 
brucellosis but surprisingly appears to 
have no inhibitory action in vitro against 
the Brucella organisms. 
One advantageous property of the drug 
is that aureomycin is active against many 
penicillin-resistant organisms as well as 
against some streptomycin-resistant 
strains. Also, bacteria do not become re-
sistant to aureomycin in the living animal. 
Aueromoycin is easily assayed because 
both serial and cup plate methods have 
been developed. 
Although much higher titres of the 
drug must be built up to produce the de-
sired or optimum effect, this effect can be 
maintained with relatively small daily 
doses. Another factor that may influence 
the use of aureomycin is that both blood 
and serum have an antagonistic effect on 
the drug. So far, however, aureomycin 
produces a more pronounced effect 
against certain organisms in the Ii ving 
animal than against those same organisms 
in an artificial culture. 
Even though the drug deteriorates 
rapidly at room temperatures in neutral 
and alkaline solutions, bacteriostasis can 
be maintained if fresh drug is ndded 
every 24 hours. In solution aureomycin 
is quite unstable and is affected by a 
variety of substances. 
Although the future of aureomycin in 
the treatment of animal diseases by the 
veterinary profession is still to be ascer-
tained, present knowledge of the drug 
points to its possible extensive use in 
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veterinary therapeutics. If this is true, 
one more link has been forged in the chain 
that will some day effectively control 
the diseases of the animal kingdom . 
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Body Minerals 
Chemical analyses show that the body 
minerals are mainly calcium and phos-
phorus which together comprise no less 
than 75 percent of the total minerals. 
The remaining 25 percent consists almost 
entirely of the four elements potassium, 
sodium, sulfur and chlorine. Magnesium 
occurs to the extent of .05 percent and 
iron to .004 percent. Spectrographic 
methods of analyses reveal the presence 
of 20 or more other elements in amounts 
too small for quantitative measurements. 
Feeding tests show that five of these 
trace elements including copper, iodine, 
manganese, cobalt and zinc are essential 
for animal life. Thus far none of the other 
trace elements occurring in the body 
have been proved to be essential for 
animal life. Pending such proof they are 
regarded as accidental contaminants. 
Of a lot of 108 cattle slaughtered at the 
Cudahy Packing Company in Denver re-
cently 76 carcasses were so bady bruised 
that the necessary trimming resulted in 
a loss of $1,200. Dr. W. T. Spencer, who 
examined the carcasses, said most of the 
damage resulted from overcrowding at 
loading and unloading shutes. 
A quarter of a million Brucella infect-
ed cows produce milk which is consumed 
raw in the United States. 
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